Amino acids

Pea Protein Market Worth $1,400 Million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, March 3, 2020

Key factors driving the growth of the pea protein market include the growing vegan population and the functional benefits and allergen-friendly nature of pea protein in food and beverage products.

Key Points: 
  • Key factors driving the growth of the pea protein market include the growing vegan population and the functional benefits and allergen-friendly nature of pea protein in food and beverage products.
  • The textured subsegment, on the basis of type, is projected to be the fastest-growing segment in the pea protein market during the forecast period.
  • Textured pea protein contains a high amount of amino acids and has better levels of lysine and glutamine than other plant-based proteins.
  • The meat substitutes subsegment is projected to account for the largest share in the pea protein market during the forecast period.

Pea Protein Market Worth $1,400 Million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, March 3, 2020

Key factors driving the growth of the pea protein market include the growing vegan population and the functional benefits and allergen-friendly nature of pea protein in food and beverage products.

Key Points: 
  • Key factors driving the growth of the pea protein market include the growing vegan population and the functional benefits and allergen-friendly nature of pea protein in food and beverage products.
  • The textured subsegment, on the basis of type, is projected to be the fastest-growing segment in the pea protein market during the forecast period.
  • Textured pea protein contains a high amount of amino acids and has better levels of lysine and glutamine than other plant-based proteins.
  • The meat substitutes subsegment is projected to account for the largest share in the pea protein market during the forecast period.

VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients

Retrieved on: 
Thursday, January 30, 2020

The FDA's IND clearance permits VistaGen to proceed with Phase 2 clinical development of AV-101 in this indication.

Key Points: 
  • The FDA's IND clearance permits VistaGen to proceed with Phase 2 clinical development of AV-101 in this indication.
  • "Current drug treatment options for levodopa-induced dyskinesia, or LID, may cause serious side effects, including hallucinations and sedation.
  • In all clinical studies to date, AV-101 has not been associated with any psychotomimetic side effects or drug-related serious adverse events.
  • "These are important milestones for our AV-101 program, both a key regulatory advance and expanded commercial protection for AV-101 in the U.S.

Investigation Report on Chinese Pregabalin Market During the Period, 2020-2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 28, 2020

The "Investigation Report on Chinese Pregabalin Market, 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on Chinese Pregabalin Market, 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • Chongqing Succeway Pharmaceutical Co., Ltd.'s Pregabalin (trade name: Lairuike) was put in the market after obtaining the production license in 2013 and is gradually taking market share from Pfizer.
  • It is estimated that Pfizer's Lyrica will continue to dominate the Chinese market from 2020 to 2024 but its market share will decline because of the price competition of China-made Pregabalin.
  • 2 Market Overview of Pregabalin in China, 2013-2018
    2.3 Investigation on Market Size of Pregabalin by Dosage Form in China, 2013-2018
    3 Investigation on Market Share of Major Pregabalin Manufacturers in China, 2013-2018
    3.3 Chongqing Succeway Pharmaceutical Co., Ltd.
    4 Sales Price of Pregabalin in China Market, 2019
    4.2.2 Chongqing Succeway Pharmaceutical Co., Ltd.(Lairuike)
    5 Prospect of Pregabalin Market, 2020-2024
    5.3 Forecast on Market Size of Pregabalin in China, 2020-2024
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005374/en/

China Pregabalin Market Analysis and Outlook 2013-2024 - Major Manufacturers' Market Shares, Sales Price, Future Prospects

Retrieved on: 
Thursday, January 23, 2020

DUBLIN, Jan. 23, 2020 /PRNewswire/ -- The "Investigation Report on Chinese Pregabalin Market, 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 23, 2020 /PRNewswire/ -- The "Investigation Report on Chinese Pregabalin Market, 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • Chongqing Succeway Pharmaceutical Co. Ltd.'s Pregabalin (trade name: Lairuike) was put in the market after obtaining the production license in 2013 and is gradually taking market share from Pfizer.
  • By sales value, in 2018, Pfizer's Lyrica had a market share of approximately 77.13%, and the rest market share was captured by the products of Chongqing Succeway Pharmaceutical Co. Ltd.
  • 2 Market Overview of Pregabalin in China, 2013-2018
    2.3 Investigation on Market Size of Pregabalin by Dosage Form in China, 2013-2018
    3 Investigation on Market Share of Major Pregabalin Manufacturers in China, 2013-2018
    3.3 Chongqing Succeway Pharmaceutical Co. Ltd.
    4 Sales Price of Pregabalin in China Market, 2019
    4.2.2 Chongqing Succeway Pharmaceutical Co. Ltd.(Lairuike)
    5 Prospect of Pregabalin Market, 2020-2024
    5.3 Forecast on Market Size of Pregabalin in China, 2020-2024
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Methionine Aminopeptidase 2 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 22, 2020

The "Methionine Aminopeptidase 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Methionine Aminopeptidase 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Methionine Aminopeptidase 2 - Pipeline Review, H2 2019'; Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) pipeline Target constitutes close to 11 molecules.
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Methionine aminopeptidase 2 is an enzyme that in humans is encoded by the METAP2 gene.
  • Methionine aminopeptidase 2 is a member of the dimetallohydrolase family is a cytosolic metalloenzyme that catalyzes the hydrolytic removal of N-terminal methionine residues from nascent proteins.

The Marquie Group Adds New Amino Acid-Based Products Ahead of Upcoming Launch of Health and Beauty Solutions Platform

Retrieved on: 
Tuesday, January 21, 2020

Our new line of amino acid-based products is portable, convenient, flavorful and the perfect addition to your diet.

Key Points: 
  • Our new line of amino acid-based products is portable, convenient, flavorful and the perfect addition to your diet.
  • The first two amino acid-based products to be released as part of the Whim platform will be AminoMints, a healthy mint containing amino acids, and AminoFizz, an effervescent drink also containing amino acids.
  • Angell continued, These products exemplify our in-house expertise at the cutting edge of the health and beauty marketplace and will complement and augment our larger Whim line of innovative solutions.
  • Management notes that these products utilize high-quality pharmaceutical-grade crystalline amino acids to ensure maximum purity and efficacy.

BioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy

Retrieved on: 
Monday, January 13, 2020

BMN 307 is an AAV5-phenylalanine hydroxylase (PAH) gene therapy designed to normalize blood phenylalanine (Phe) concentration levels in patients with PKU.

Key Points: 
  • BMN 307 is an AAV5-phenylalanine hydroxylase (PAH) gene therapy designed to normalize blood phenylalanine (Phe) concentration levels in patients with PKU.
  • The Company is actively preparing regulatory submissions to open additional clinical sites in other countries.BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.
  • BMN 307 follows BioMarin's first investigational gene therapy clinical program: valoctocogene roxaparvovec to treat severe hemophilia A, currently in Phase 3.
  • The company has two approved PKU therapies, and the investigational gene therapy BMN 307 is currently in development.

Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the U.S. Patent and Trademark Office

Retrieved on: 
Thursday, December 5, 2019

Vlad Coric, M.D., CEO of Biohaven commented, "We are particularly excited about the grant of this composition of matter patent in anticipation of upcoming results from multiple troriluzole Phase 2/3 clinical trials.

Key Points: 
  • Vlad Coric, M.D., CEO of Biohaven commented, "We are particularly excited about the grant of this composition of matter patent in anticipation of upcoming results from multiple troriluzole Phase 2/3 clinical trials.
  • The USPTO's issuance of this patent enhances the strength of our intellectual property protection around glutamate modulating agents and troriluzole.
  • Troriluzole is a third-generation prodrug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body.
  • The use of certain words, including the "believe" and "will" and similar expressions are intended to identify forward-looking statements.

Evecxia Inc. Appoints Jacob Jacobsen, PhD, as Chief Scientific Officer

Retrieved on: 
Thursday, December 5, 2019

Evecxia, Inc., a biopharmaceutical company focused on the treatment of neuropsychiatric diseases, today announced that it has appointed Jacob Jacobsen, PhD, as its Chief Scientific Officer (CSO).

Key Points: 
  • Evecxia, Inc., a biopharmaceutical company focused on the treatment of neuropsychiatric diseases, today announced that it has appointed Jacob Jacobsen, PhD, as its Chief Scientific Officer (CSO).
  • While at Duke University, Dr. Jacobsen built the 5-hydroxytryptophan slow-release (5-HTP SR) scientific and technical rationale undergirding EVX-101.
  • I am happy to be working with Jacob and we look forward to his contributions and welcome him to our dedicated and focused team.
  • For more information about the Evecxia and its product candidates, please visit www.evecxia.com or contact [email protected] .